TY - JOUR
T1 - Gemcitabine in hematologic malignancies
AU - Nabhan, Chadi
AU - Krett, Nancy
AU - Gandhi, Varsha
AU - Rosen, Steven
PY - 2001/11/1
Y1 - 2001/11/1
N2 - Gemcitabine is a pyrimidine analogue that showed significant activity in solid malignancies. Gemcitabine acts by inhibiting DNA synthesis through chain termination and ribonucleotide reductase inhibition. During initial phase I and II studies, gemcitabine had a low toxicity profile and was well tolerated as a single agent and in combination therapy. Recently, there has been more interest in studying the activity of gemcitabine in hematologic malignancies. Gemcitabine demonstrated good activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias. There is a preponderance of evidence on the activity of gemcitabine in vitro in myeloma and leukemic cell lines. The activity of gemcitabine in these disorders will pave the way for incorporating this agent into the early phases of therapy.
AB - Gemcitabine is a pyrimidine analogue that showed significant activity in solid malignancies. Gemcitabine acts by inhibiting DNA synthesis through chain termination and ribonucleotide reductase inhibition. During initial phase I and II studies, gemcitabine had a low toxicity profile and was well tolerated as a single agent and in combination therapy. Recently, there has been more interest in studying the activity of gemcitabine in hematologic malignancies. Gemcitabine demonstrated good activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias. There is a preponderance of evidence on the activity of gemcitabine in vitro in myeloma and leukemic cell lines. The activity of gemcitabine in these disorders will pave the way for incorporating this agent into the early phases of therapy.
UR - http://www.scopus.com/inward/record.url?scp=0034762891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034762891&partnerID=8YFLogxK
U2 - 10.1097/00001622-200111000-00015
DO - 10.1097/00001622-200111000-00015
M3 - Review article
C2 - 11673693
AN - SCOPUS:0034762891
SN - 1040-8746
VL - 13
SP - 514
EP - 521
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -